title: [Nicardipine in the treatment of Raynaud's phenomenon].
abstract: The efficacy of the calcium-channel blocker nicardipine in the treatment of Raynaud's phenomenon was assessed in a double-blind, randomised, crossover trial in 20 patients. Each patient received 2 weeks of nicardipine 20 mg three times daily and 2 weeks of placebo. Nicardipine significantly improved the frequency and severity of Raynaud's phenomenon. An open study during 2 months in 30 patients confirmed the effectiveness of nicardipine (20-40 mg 3 times daily). Side effects (headache, flushing, ankle oedema) were frequent but usually mild. We conclude that nicardipine is effective in the treatment of Raynaud's phenomenon.
authors.forename: A
authors.initials: A
authors.lastname: Kahan
authors.forename: B
authors.initials: B
authors.lastname: Amor
authors.forename: C J
authors.initials: CJ
authors.lastname: Menkès
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy*
chemical_list: D009529:Nicardipine
vernacular_title: La nicardipine dans le traitement du phénomène de Raynaud.